Shailesh Patel, DO
Nephrology · Tempe, AZNPI 1144274861
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $6,424 of the $9,910 with a category attached, or 64.8%. Medtronic accounts for 64.8% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2019 at $6,770 and has fallen 82.0% since, to $1,221 in 2025. Among nephrology clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 172 payments — averaging $57.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$6K
- Amgen$612
- Otsuka America Pharmaceutical, Inc.$493
- AstraZeneca$451
- Travere Therapeutics, Inc.$209
- OPKO Pharmaceuticals, LLC$175
- plus $2K from 21 others
What the payments were for
- Royalty or licence$6,42465%
- Food & beverage$3,39034%
- Education$961%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 1 | $6,424 |
| Amgen(2 entities) | 35 | $612 |
| Otsuka America Pharmaceutical, Inc. | 24 | $493 |
| AstraZeneca(2 entities) | 25 | $451 |
| Travere Therapeutics, Inc. | 9 | $209 |
| OPKO Pharmaceuticals, LLC | 9 | $175 |
| Akebia Therapeutics Inc | 7 | $156 |
| Ardelyx, Inc. | 8 | $144 |
| Vantive US Healthcare LLC | 1 | $128 |
| Novartis | 6 | $124 |
| Calliditas Therapeutics US Inc. | 6 | $103 |
| Mallinckrodt Hospital Products Inc. | 4 | $102 |
| Daiichi Sankyo Inc. | 4 | $94 |
| Chiesi USA, Inc. | 1 | $93 |
| Bayer | 5 | $87 |
| Boehringer Ingelheim | 4 | $83 |
| GSK | 5 | $81 |
| Lilly USA, LLC | 4 | $77 |
| Vifor Pharma, Inc. | 4 | $68 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Fresenius USA Marketing, Inc. | 1 | $24 |
| Novo Nordisk | 1 | $23 |
| Cormedix Inc. | 1 | $21 |
| Sanofi | 1 | $18 |
| Apellis Pharmaceuticals, Inc. | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VenaSeal$6,424
How this compares
$9,910 in reported general payments places this provider in the 90th percentile of 259 nephrology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 77 | $65,460 |
| JardianceEmpagliflozin | 26 | $30,858 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $22,142 |
| Clonidine | 16 | $5,453 |
| Hydralazine Hcl | 296 | $4,490 |
| Sevelamer Carbonate | 26 | $3,610 |
| Doxazosin Mesylate | 124 | $3,136 |
| Cinacalcet Hcl | 24 | $2,921 |
| Amlodipine Besylate | 449 | $2,811 |
| Nifedipine ErNifedipine | 84 | $2,590 |
| Losartan Potassium | 199 | $1,949 |
| Potassium Chloride | 102 | $1,742 |
| Lisinopril | 311 | $1,727 |
| Calcitriol | 151 | $1,608 |
| Bumetanide | 57 | $1,243 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $451 | $65,46077 claims |
| Boehringer IngelheimJardiance | $83 | $30,85826 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $17 | $65038 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 259 nephrology providers in Arizona.
Other nephrology in Tempe
- Theodore TzeremasTempe$6K
- Rajan KapoorTempe$6K
- Clyde MendoncaTempe$5K
- Randy CooperPeoria$597K
- Minesh RajpalPeoria$403K
- Umar WaheedPeoria$150K
- Amer KhanPeoria$71K
- Samer Bani HaniPhoenix$54K
- Aneesha ShettyTucson$34K
- Leslie ThomasPhoenix$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.